Pharvaris NV Ordinary Shares PHVS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PHVS is a good fit for your portfolio.
News
-
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer
-
Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference
-
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses
-
Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
-
Pharvaris to Participate in the Leerink Global Biopharma Conference 2024
-
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting
-
Pharvaris Announces Extraordinary Meeting of Shareholders
Trading Information
- Previous Close Price
- $22.77
- Day Range
- $22.20–25.44
- 52-Week Range
- $7.93–33.00
- Bid/Ask
- $23.13 / $38.40
- Market Cap
- $1.26 Bil
- Volume/Avg
- 85,067 / 91,509
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Pharvaris NV is a clinical-stage company. It is focused on the discovery and development and commercialization of therapies for rare diseases with significant unmet need, initially focused on angioedema and other bradykinin-mediated diseases. The company's activities are considered to be one segment which comprises the discovery, development and commercialization of oral bradykinin-B2-receptor antagonists .
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 82
- Website
- https://www.pharvaris.com
Comparables
Valuation
|
Metric
|
PHVS
|
NAMS
|
QURE
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.88 | 6.29 | 1.05 |
Price/Sales | — | 128.23 | 13.72 |
Price/Cash Flow | — | — | — |
Price/Earnings
PHVS
NAMS
QURE
Financial Strength
|
Metric
|
PHVS
|
NAMS
|
QURE
|
|---|---|---|---|
Quick Ratio | 9.85 | 6.86 | 8.44 |
Current Ratio | 10.46 | 6.95 | 8.85 |
Interest Coverage | — | — | −6.85 |
Quick Ratio
PHVS
NAMS
QURE
Profitability
|
Metric
|
PHVS
|
NAMS
|
QURE
|
|---|---|---|---|
Return on Assets (Normalized) | −50.56% | −34.73% | −35.54% |
Return on Equity (Normalized) | −56.14% | −39.45% | −82.34% |
Return on Invested Capital (Normalized) | −56.14% | −41.57% | −55.12% |
Return on Assets
PHVS
NAMS
QURE
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Pzsscyrsm | Cjvpr | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Tjvrkkvw | Pjdhtk | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ncxclcn | Hxqnlj | $97.8 Bil | |
MRNA
| Moderna Inc | Gffzpjsg | Xjhf | $41.3 Bil | |
ARGX
| argenx SE ADR | Nlvvppfs | Pktn | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Pppmdcg | Qrst | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Mxcjfjclp | Bmtmym | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Mrfqjlkhx | Xzbvxx | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Jvlplkmcb | Vqmdpf | $12.5 Bil | |
INCY
| Incyte Corp | Dkjhjxpsr | Vrnryz | $11.6 Bil |